P2Y
P2Y12 inhibitor
antiplatelet
atrial fibrillation
oral anticoagulation
percutaneous coronary intervention
Journal
Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
11
09
2019
revised:
18
12
2019
accepted:
11
01
2020
pubmed:
9
2
2020
medline:
17
2
2021
entrez:
9
2
2020
Statut:
ppublish
Résumé
This study aimed to compare the safety and efficacy of third-generation P2Y We performed a systematic review including both prospective and retrospective studies that compared dual and triple antithrombotic regimens for bleeding and major adverse cardiac events (MACE) in patients with AF undergoing PCI. We analysed rates of bleeding and MACE by P2Y A total of 22 014 patients were analysed from the seven studies included. Among patients treated with both OAC and P2Y Based on this meta-analysis, the use of clopidogrel is associated with a lower rate of bleeding compared with ticagrelor or prasugrel in patients with AF on OAC undergoing PCI.
Identifiants
pubmed: 32034008
pii: heartjnl-2019-315963
doi: 10.1136/heartjnl-2019-315963
pmc: PMC7265981
mid: NIHMS1576719
doi:
Substances chimiques
Anticoagulants
0
Purinergic P2Y Receptor Antagonists
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
575-583Subventions
Organisme : American Heart Association-American Stroke Association
ID : 19CDA34760021
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: JH has received honoraria from Medtronic, Abbott, Boston Scientific, Biotronik, Janssen Pharmaceutical, Bristol-Myers Squibb and Bio-sense-Webster and has received research grants from Biosense-Webster and Biotronik. GF, as CCEP Fellowship Training Program Director, receives fellowship training programme stipends from Medtronic, Biotronik, Biosense Webster, St. Jude/Abbott and Boston Scientific, Inc and has stock options or co-ownership in Acutus, Inc, toSense, Inc and Perminova, Inc.
Références
N Engl J Med. 2019 Oct 17;381(16):1524-1534
pubmed: 31475799
J Am Coll Cardiol. 2019 Jul 9;74(1):104-132
pubmed: 30703431
Clin Cardiol. 2016 Jan;39(1):19-23
pubmed: 26748815
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1445-1461
pubmed: 27535163
Circulation. 1994 Jul;90(1):61-8
pubmed: 8026047
Thromb Res. 2015 Jan;135(1):26-30
pubmed: 25467434
J Am Coll Cardiol. 2014 Dec 23;64(24):e139-e228
pubmed: 25260718
Eur Heart J. 2006 May;27(9):1038-47
pubmed: 16476694
Ther Adv Drug Saf. 2017 Oct;8(10):319-328
pubmed: 29593860
N Engl J Med. 2017 Oct 5;377(14):1319-1330
pubmed: 28844192
Pharmacotherapy. 2014 Oct;34(10):1077-90
pubmed: 25164528
N Engl J Med. 2019 Apr 18;380(16):1509-1524
pubmed: 30883055
Pharmacotherapy. 2009 Sep;29(9):1089-102
pubmed: 19698014
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
J Am Coll Cardiol. 2013 May 21;61(20):2060-6
pubmed: 23524219
N Engl J Med. 2009 Sep 10;361(11):1045-57
pubmed: 19717846
Arch Intern Med. 2010 Sep 13;170(16):1433-41
pubmed: 20837828
Br J Clin Pharmacol. 2007 Apr;63(4):421-30
pubmed: 17076696
N Engl J Med. 2016 Dec 22;375(25):2423-2434
pubmed: 27959713
Eur Heart J. 2016 Oct 7;37(38):2893-2962
pubmed: 27567408
J Am Coll Cardiol. 2016 Sep 6;68(10):1082-115
pubmed: 27036918
N Engl J Med. 2007 Nov 15;357(20):2001-15
pubmed: 17982182
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
JACC Cardiovasc Interv. 2015 Dec 21;8(14):1880-9
pubmed: 26718518
N Engl J Med. 2012 Jan 5;366(1):9-19
pubmed: 22077192
Lancet. 2013 Mar 30;381(9872):1107-15
pubmed: 23415013
N Engl J Med. 2017 Oct 19;377(16):1513-1524
pubmed: 28844193
Circulation. 2014 Dec 2;130(23):e199-267
pubmed: 24682347
J Am Coll Cardiol. 2015 Aug 18;66(7):777-787
pubmed: 26271059
BMJ. 2011 Jul 22;343:d4002
pubmed: 21784880